Jun 1, 2026 06:59AM
Jun 1, 2026 06:59AM
Feb 17, 2026 05:31PM
Feb 17, 2026 07:00AM
Feb 17, 2026 06:59AM
Dec 11, 2025 06:59AM
Dec 11, 2025 06:59AM U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Oct 27, 2025 06:59AM
Oct 27, 2025 06:59AM
Oct 1, 2025 01:20PM
Aug 4, 2025 04:16PM
Aug 4, 2025 04:16PM
Jul 21, 2025 07:00AM
Jul 21, 2025 06:59AM Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Glob
Apr 8, 2025 03:39PM
Apr 8, 2025 03:36PM
Mar 7, 2025 06:59AM
Mar 7, 2025 06:59AM
Feb 24, 2025 06:59AM
Feb 24, 2025 06:59AM
Feb 6, 2025 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
Jan 31, 2025 06:59AM
Jan 31, 2025 06:59AM
Dec 11, 2024 09:44AM
Oct 31, 2024 06:59AM
Sep 27, 2024 08:05AM
Sep 27, 2024 06:07AM
Sep 23, 2024 07:28AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
Aug 28, 2024 02:01AM
Aug 21, 2024 07:00AM
Aug 21, 2024 06:59AM
Jul 26, 2024 06:59AM
Jul 23, 2024 06:35AM
Jun 17, 2024 09:45AM
May 21, 2024 06:59AM Bristol-Myers Squibb (BMY) Announces Update FDA Action Date for Subcutaneous Nivolumab
May 21, 2024 06:59AM
May 6, 2024 06:59AM
May 6, 2024 06:59AM
Apr 25, 2024 06:59AM
Apr 25, 2024 05:22AM
Apr 8, 2024 11:31AM
Apr 8, 2024 11:30AM KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or
Apr 1, 2024 07:31AM
Apr 1, 2024 07:30AM
Mar 28, 2024 04:07PM
Mar 28, 2024 04:05PM
Mar 18, 2024 09:52AM
Mar 18, 2024 08:45AM
Mar 18, 2024 08:44AM Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Feb 20, 2024 06:59AM

15,439 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All